Nymox Pharmaceutical Corp. has announced the initiation of patient enrollment for a Phase II trial of NX-1207 for the treatment of men with low-risk, localized prostate cancer. This product is already in Phase III clinical trials in Europe and the USA for the treatment of men with benign prostatic hyperplasia (BPH). … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: localized, low risk, NX-1207, trial | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site
